Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01

Yunda Huang(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Maria P. Lemos(University of Pennsylvania), Srilatha Edupuganti(Emory University), Richard A. Koup(Aaron Diamond AIDS Research Center), Myron S. Cohen(University of North Carolina at Chapel Hill), Edith Swann(National Institutes of Health), Peter L. Anderson(University of Colorado Denver), Lawrence Corey(Fred Hutch Cancer Center), Heather Angier(Fred Hutch Cancer Center), Shelly Karuna(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Deborah Donnell(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Lúcio Gama(National Institutes of Health), Joshua A. Weiner(Dartmouth College), Margaret E. Ackerman(Dartmouth College), M. Juliana McElrath(Fred Hutch Cancer Center), Peter B. Gilbert(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), P. Andrew(Family Health International 360), Yasmin Azzam(Fred Hutch Cancer Center), Lily Zhang(Fred Hutch Cancer Center), John Hural(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Nyaradzo Mgodi(University of Zimbabwe), Evgenii Morgan(Fred Hutch Cancer Center), Michal Juraska(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Nature Communications
November 28, 2023
Cited by 8


Related Papers